We work with and support leading researchers, doctors, and public health experts who share our vision for transforming the lives of people with serious diseases, their families and society.
Investigator Sponsored Studies
Our Investigator Sponsored Study program supports independent, investigator-sponsored research designed to advance scientific knowledge of disease states, patient populations and medical treatment, in alignment with our clinical and nonclinical areas of interest. We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.
Cystic Fibrosis FDA-Approved Compound-Only Requests
We’re interested in supporting cystic fibrosis research to strengthen scientific community knowledge through compound contributions to investigators. Requests through this program will be reviewed for in vitro or ex vivo studies only. Investigators are encouraged to apply to this program by sending their non-confidential research objective, detailed experimental plan and requested material quantity to CompoundRequests@vrtx.com.
Cystic Fibrosis Research Innovation Award (CF RIA)
The Vertex CF Research Innovation Awards are highly competitive grants created to inspire and support the next generation of M.D.s and Ph.Ds. who are working to advance the understanding of CF and establish their careers as CF researchers. The awards fall into two categories: Independent and Mentored.
Independent Research Innovation Awards provide grants of $750,000 dispersed over three years to support newly independent faculty members as they establish their own research programs with outstanding promise in CF. Up to two awards will be given annually in this category.
Mentored Research Innovation Awards provide grants of up to $125,000 dispersed over two years to support mentored projects with established CF researchers. Up to four awards in this category will be given annually.
Together these programs will provide up to $10 million over the next five years. Applications are reviewed and selected by an independent steering committee.
Vertex Innovation Awards (VIA)
VIA supports innovative and collaborative clinical research that may improve the care of patients with CF. Applications for clinical research projects are welcomed from across the entire field of CF and are to be led by an individual or individuals with an established career interest in CF. For 2019, the VIA program has expanded to allow applications from Argentina, Australia, Brazil, Canada, Columbia, Europe*, Israel, New Zealand, and the United States. Applicants are reviewed and selected by the independent VIA Committee of external experts who will select up to four projects to support with grants up to a total of €750,000 (Euros).
*Austria, Belgium, Denmark, France, Germany, Greece, Italy, Ireland, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK
Circle of Care
Circle of Care is a competitive grant opportunity that funds innovative patient-centric programs for the CF community. Each year Vertex awards up to $1M in Circle of Care grants.
Vertex accepts CF Circle of Care grant applications that focus on one or more of the following categories:
- Programs that support persons with CF live a fuller, more engaged lifestyle
- Programs that address the psycho-social challenges patients and caregivers face with CF
- Programs that improve the overall support of the family members of patients with CF
- Programs or tools that support patients with CF taking more ownership of their healthcare
- Programs focused on the education of patients with CF, including topics on transition and the importance of following healthcare provider's recommendations regarding care, and navigating new environments with CF
Clinical Trial Data Sharing
Vertex is committed to advancing medical science and improving patient health through responsible sharing of clinical trial data. Requests for clinical trial data from qualified researchers that include a complete research proposal and pre-specified analysis plan will be considered.